What is a leukemoid reaction and how should it be evaluated and managed?

Leukemoid Reaction: Definition, Evaluation, and Management

A leukemoid reaction is a benign, reactive elevation of white blood cells (WBC) typically exceeding 50,000 cells/μL that mimics leukemia but is caused by an underlying non-hematologic condition—most commonly severe infection, malignancy, or acute physiologic stress—and carries a grave prognosis with mortality rates approaching 38-61% depending on the underlying cause. 1, 2, 3

Definition and Clinical Significance

A leukemoid reaction represents a marked leukocytosis, classically defined as WBC >50,000 cells/μL (though some sources use >30,000 cells/μL as the threshold), occurring in the absence of primary hematologic malignancy 1, 2. This condition affects approximately 0.59% of hospitalized adults and is associated with significant morbidity and mortality 2.

The prognosis is particularly poor in elderly patients, those with sepsis, and patients with prolonged leukemoid reactions lasting >1 day, with in-hospital mortality reaching 61.5% in the latter group 2.

Differential Diagnosis: Distinguishing from Leukemia

The critical first step is excluding chronic myelogenous leukemia (CML) and chronic neutrophilic leukemia (CNL) 1. Key distinguishing features include:

Features Favoring Leukemoid Reaction:

• Absence of Philadelphia chromosome (BCR-ABL fusion gene negative by cytogenetics or PCR)
• Toxic granulation, Döhle bodies, and cytoplasmic vacuolization in neutrophils
• Elevated leukocyte alkaline phosphatase (LAP) score
• Absence of basophilia
• Rapid resolution with treatment of underlying cause

Features Favoring CML:

• Philadelphia chromosome positive (t(9;22) translocation) 4
• BCR-ABL transcripts on RT-PCR 4
• Basophilia and eosinophilia
• Low LAP score
• Splenomegaly
• Full spectrum of myeloid maturation including increased myelocytes and metamyelocytes 4

Etiologies: A Systematic Approach

The underlying causes follow a predictable pattern based on recent cohort studies 2, 3:

Primary Causes (in order of frequency):

1. Infection (47-59% of cases) 2, 3

   • Bacterial sepsis (most common)
   • Clostridium difficile colitis (higher WBC counts correlate with positive toxin, P=0.001) 2
   • Positive blood cultures correlate with higher WBC counts (P=0.017) 2
   • Multiple organisms may be involved 3

2. Ischemia/Acute Stress (28%) 2

   • Myocardial infarction
   • Acute hemorrhage
   • Acute hemolysis
   • Diabetic ketoacidosis 5

3. Malignancy (16-17%) 2, 3

   • Paraneoplastic syndrome (particularly pancreatic, breast, colon, cholangiocarcinoma) 6
   • Metastatic disease to bone marrow
   • Extremely poor prognosis when present 6

4. Inflammation (7%) 2

   • Severe inflammatory conditions
   • Drug reactions (e.g., ferric carboxymaltose) 7

5. Obstetric Causes (7%) 2

6. Other Causes

   • Glucocorticoid administration 8
   • Thrombotic events 8
   • Hemoglobinopathies (rare) 9

Diagnostic Evaluation Algorithm

Step 1: Confirm Leukemoid Reaction

• WBC count >50,000 cells/μL (or >30,000 cells/μL by some definitions)
• Complete blood count with differential
• Peripheral blood smear examination

Step 2: Exclude Primary Hematologic Malignancy

• Cytogenetics for Philadelphia chromosome (BCR-ABL by FISH or PCR) 4, 1
• Bone marrow biopsy if diagnosis unclear
• LAP score (elevated in leukemoid reaction, low in CML)

Step 3: Identify Underlying Cause

Infectious workup:

• Blood cultures (at least 2 sets)
• C. difficile toxin assay
• Urinalysis and urine culture
• Chest imaging
• Site-specific cultures based on clinical presentation

Cardiovascular/stress evaluation:

• Troponin, ECG for myocardial ischemia
• Lactate for tissue hypoperfusion
• Hemoglobin trend for acute hemorrhage

Malignancy screening:

• CT chest/abdomen/pelvis if no obvious source
• Tumor markers if malignancy suspected
• Consider bone marrow biopsy to exclude marrow infiltration

Laboratory markers:

• Inflammatory markers (CRP, ESR)
• Metabolic panel (glucose, electrolytes for DKA)
• Liver function tests
• Coagulation studies

Step 4: Risk Stratification

High-risk features predicting mortality 2, 3:

• Age >75 years (OR=1.051 per year, P<0.001)
• Sepsis diagnosis (OR=3.752, P=0.001)
• Any infectious diagnosis (OR=2.574, P=0.014)
• Lower hemoglobin levels
• Increased segmented neutrophil count
• Prolonged leukemoid reaction (>1 day duration)

Management Approach

Immediate Management

The cornerstone of management is aggressive treatment of the underlying condition—there is no specific therapy for the leukemoid reaction itself 1, 2, 3.

1. For Infection-Related Leukemoid Reaction:

   • Broad-spectrum antibiotics (80.9% of patients require antimicrobials) 2
   • Source control (drainage, debridement)
   • Hemodynamic support for sepsis
   • Note: In ECMO patients, leukemoid reactions rarely indicate new infection (only 7% in one series), suggesting low utility for broadening antimicrobials based solely on WBC elevation 8

2. For Hyperleukocytosis with Symptoms:

   • If WBC >100,000 cells/μL with leukostasis symptoms (pulmonary infiltrates, retinal/cerebral hemorrhages):
     • Hydroxyurea 50-60 mg/kg/day until WBC <10-20 × 10⁹/L 10
     • Leukapheresis may be considered but has no proven impact on long-term outcomes 10
     • Avoid excessive RBC transfusions until WBC reduced (increases viscosity) 10
     • Tumor lysis syndrome prophylaxis: hydration, allopurinol or rasburicase, urine pH control 10

3. For Malignancy-Associated Leukemoid Reaction:

   • Systemic chemotherapy for underlying malignancy
   • Supportive care (cytoreductive therapy, plasma exchange, continuous hemofiltration may provide transient benefit) 6
   • Prognosis is extremely poor; focus on goals of care discussions 6

4. For Stress/Ischemia-Related:

   • Treat underlying condition (revascularization for MI, volume resuscitation for hemorrhage, insulin for DKA)
   • WBC typically normalizes rapidly with correction of precipitant 5

Monitoring and Follow-up

• Serial WBC counts to document resolution
• Median duration of leukemoid reaction is 1 day 2
• Persistent elevation >1 day warrants reassessment for uncontrolled underlying cause or alternative diagnosis
• Resolution confirms reactive nature and excludes primary hematologic malignancy

Critical Pitfalls to Avoid

1. Assuming leukemoid reaction equals infection: Multiple etiologies exist; systematic evaluation is mandatory 2, 3

2. Failing to exclude CML: Always obtain BCR-ABL testing before attributing leukocytosis to reactive causes 1

3. Overtreatment in specific contexts: In ECMO patients, leukemoid reactions are often multifactorial (thrombus, glucocorticoids, known infections) and rarely indicate new infection 8

4. Underestimating mortality risk: This is not a benign finding—38-61% in-hospital mortality demands aggressive management of underlying cause 2, 3

5. Unnecessary leukapheresis: While tempting for extreme leukocytosis, it has no proven survival benefit and should be reserved for symptomatic leukostasis 10

6. Missing paraneoplastic syndrome: In patients with known malignancy and leukemoid reaction, prognosis is dismal and warrants frank prognostic discussions 6